Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06057454 · ClinicalTrials.gov registry record · Phase 1
R-5280 in Newly Diagnosed Patients With Type 1 Diabetes
A Phase 1 study, sponsored by Rise Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT06057454: Completed Phase 1 study, sponsored by Rise Therapeutics.
NCT06057454 is a Phase 1 study that has completed, run by Rise Therapeutics. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06057454, a Phase 1 study, has completed, sponsored by Rise Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
Evaluating the adverse events and tolerance of R-5280 in Mitigating Type 1 Diabetes in Newly Diagnosed Patients
Primary Outcome
The number of participants with treatment-related adverse events as evaluated by CTCAE v5.0, will be reviewed to see the results from baseline in toxicology scores at 12 Weeks compared to placebo.
Interventions
- OTHER Placebo
- DRUG R-5280
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2023-12-05 |
| Est. Completion | 2025-11-05 |
| Phase | Phase 1 |
What the finished NCT06057454 record still lists
NCT06057454 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06057454 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06057454 about?
NCT06057454 is a clinical study titled "R-5280 in Newly Diagnosed Patients With Type 1 Diabetes". Evaluating the adverse events and tolerance of R-5280 in Mitigating Type 1 Diabetes in Newly Diagnosed Patients
What is the current status of trial NCT06057454?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2023-12-05. Estimated completion is 2025-11-05.
What interventions are being tested in trial NCT06057454?
The interventions under investigation include: Placebo (OTHER), R-5280 (DRUG).
Who is sponsoring clinical trial NCT06057454?
This trial is sponsored by Rise Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06057454's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI